Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Polymorphisms that are associated with drug-induced liver injury from statins

The most recent issue of Gastroenterology examines the association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study.

News image

Dr Ann Daly and colleagues from the United Kingdom performed a genome-wide association study (GWAS) to identify genetic risk factors for drug-induced liver injury from licensed drugs without previously reported genetic risk factors.

The research team performed a GWAS of 862 persons with drug-induced liver injury, and 10,588 population-matched controls. 

The first set of cases was recruited before 2009 in Europe, and the United States. 

The second set of cases were identified from 2009 through 2013 from international collaborative studies performed in Europe, the United States, and South America. 

For the GWAS, the research team included only cases with patients of European ancestry associated with a particular drug. 

The polymorphism on chromosome 2 was associated with cholestatic and mixed drug-induced liver injury
Gastroenterology
The researchers used DNA samples from all subjects to analyze HLA genes and single nucleotide polymorphisms. 

After the discovery analysis was concluded, the team validated their findings using data from 283 European patients with diagnosis of drug-induced liver injury associated with various drugs.

The team associated drug-induced liver injury with rs114577328, and with rs72631567 on chromosome 2. 

The researchers found that the association with A*33:01 was mediated by large effects for terbinafine-, fenofibrate-, and ticlopidine-related drug-induced liver injury. 

The variant on chromosome 2 was associated with drug-induced liver injury from a variety of drugs. 

Further phenotypic analysis indicated that the association between drug-induced liver injury, and A*33:01 was significant genome wide for cholestatic and mixed drug-induced liver injury, but not for hepatocellular drug-induced liver injury.

The team noted that the polymorphism on chromosome 2 was associated with cholestatic and mixed drug-induced liver injury as well as hepatocellular drug-induced liver injury. 

The researchers identified an association between rs28521457, and only hepatocellular drug-induced liver injury. 

The team did not associate any specific drug classes with genetic polymorphisms, except for statin-associated drug-induced liver injury, which was associated with rs116561224 on chromosome 18. 

The researchers validated the association between A*33:01 terbinafine- and sertraline-induced drug-induced liver injury. 

The team could not validate the association between drug-induced liver injury and rs72631567, rs28521457, or rs116561224.

Dr Daly's team concludes, "In a GWAS of persons of European descent with drug-induced liver injury, we associated HLA-A*33:01 with drug-induced liver injury due to terbinafine and possibly fenofibrate and ticlopidine."

"We identified polymorphisms that appear to be associated with drug-induced liver injury from statins, as well as 2 non-drug-specific risk factors."

Gastroenterol 2017: 152(5): 1078–1089 
10 April 2017

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us